136 related articles for article (PubMed ID: 11086033)
1. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
Kacha AK; Fallarino F; Markiewicz MA; Gajewski TF
J Immunol; 2000 Dec; 165(11):6024-8. PubMed ID: 11086033
[TBL] [Abstract][Full Text] [Related]
2. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.
Fallarino F; Gajewski TF
J Immunol; 1999 Oct; 163(8):4109-13. PubMed ID: 10510345
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
Fallarino F; Ashikari A; Boon T; Gajewski TF
Int Immunol; 1997 Sep; 9(9):1259-69. PubMed ID: 9310829
[TBL] [Abstract][Full Text] [Related]
4. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
Fallarino F; Uyttenhove C; Boon T; Gajewski TF
J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984
[TBL] [Abstract][Full Text] [Related]
5. Distinct requirements for IFNs and STAT1 in NK cell function.
Lee CK; Rao DT; Gertner R; Gimeno R; Frey AB; Levy DE
J Immunol; 2000 Oct; 165(7):3571-7. PubMed ID: 11034357
[TBL] [Abstract][Full Text] [Related]
6. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
Ostrand-Rosenberg S; Clements VK; Terabe M; Park JM; Berzofsky JA; Dissanayake SK
J Immunol; 2002 Nov; 169(10):5796-804. PubMed ID: 12421960
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
8. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
[TBL] [Abstract][Full Text] [Related]
9. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity.
Eguchi J; Kuwashima N; Hatano M; Nishimura F; Dusak JE; Storkus WJ; Okada H
J Immunol; 2005 Jun; 174(11):7194-201. PubMed ID: 15905564
[TBL] [Abstract][Full Text] [Related]
10. Single cell analysis reveals that IL-4 receptor/Stat6 signaling is not required for the in vivo or in vitro development of CD4+ lymphocytes with a Th2 cytokine profile.
Jankovic D; Kullberg MC; Noben-Trauth N; Caspar P; Paul WE; Sher A
J Immunol; 2000 Mar; 164(6):3047-55. PubMed ID: 10706693
[TBL] [Abstract][Full Text] [Related]
11. Analysis of cytokine functions in graft rejection by gene expression profiles.
Liang Y; Christopher K; DeFina R; Cidado J; He H; Haley KJ; Finn PW; Perkins DL
Transplantation; 2003 Dec; 76(12):1749-58. PubMed ID: 14688527
[TBL] [Abstract][Full Text] [Related]
12. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells.
Jensen SM; Meijer SL; Kurt RA; Urba WJ; Hu HM; Fox BA
J Immunol; 2003 Feb; 170(4):2014-21. PubMed ID: 12574371
[TBL] [Abstract][Full Text] [Related]
13. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
Gajewski TF; Fallarino F; Uyttenhove C; Boon T
J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
[TBL] [Abstract][Full Text] [Related]
14. IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL.
Levraud JP; Duffour MT; Cordier L; Perricaudet M; Haddada H; Kourilsky P
J Immunol; 1997 Apr; 158(7):3335-43. PubMed ID: 9120291
[TBL] [Abstract][Full Text] [Related]
15. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.
Ostrand-Rosenberg S; Grusby MJ; Clements VK
J Immunol; 2000 Dec; 165(11):6015-9. PubMed ID: 11086031
[TBL] [Abstract][Full Text] [Related]
16. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
Sinha P; Clements VK; Ostrand-Rosenberg S
J Immunol; 2005 Jan; 174(2):636-45. PubMed ID: 15634881
[TBL] [Abstract][Full Text] [Related]
17. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors.
Liu B; Podack ER; Allison JP; Malek TR
J Immunol; 1996 Feb; 156(3):1117-25. PubMed ID: 8557987
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the individual and cross-reactive antigens involved in the anti-tumor immunity induced by use of an H-2K-erbB recombinant gene transfectant.
Ding LN; Yoshida T; Isobe K; Rahman SM; Nagase F; Yokochi T; Kawashima K; Nakashima I
Jpn J Cancer Res; 1991 Jul; 82(7):841-7. PubMed ID: 1679057
[TBL] [Abstract][Full Text] [Related]
20. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
